Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCapital LeasesCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current LiabilitiesPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - AccuredRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios

SAB Biotherapeutics (SABSW) Accounts Payables (2020 - 2025)

SAB Biotherapeutics' Accounts Payables history spans 6 years, with the latest figure at $6.6 million for Q4 2025.

  • For Q4 2025, Accounts Payables rose 288.5% year-over-year to $6.6 million; the TTM value through Dec 2025 reached $6.6 million, up 288.5%, while the annual FY2025 figure was $6.6 million, 288.5% up from the prior year.
  • Accounts Payables reached $6.6 million in Q4 2025 per SABSW's latest filing, up from $3.0 million in the prior quarter.
  • In the past five years, Accounts Payables ranged from a high of $11.9 million in Q1 2022 to a low of $945927.0 in Q4 2023.
  • Average Accounts Payables over 5 years is $3.5 million, with a median of $2.5 million recorded in 2025.
  • Peak YoY movement for Accounts Payables: plummeted 89.42% in 2023, then soared 288.5% in 2025.
  • A 5-year view of Accounts Payables shows it stood at $4.5 million in 2021, then dropped by 17.48% to $3.7 million in 2022, then plummeted by 74.29% to $945927.0 in 2023, then soared by 79.16% to $1.7 million in 2024, then skyrocketed by 288.5% to $6.6 million in 2025.
  • Per Business Quant, the three most recent readings for SABSW's Accounts Payables are $6.6 million (Q4 2025), $3.0 million (Q3 2025), and $2.6 million (Q2 2025).